Zelnecirnon - RAPT Therapeutics
Alternative Names: 14C-RPT193; FLX-193; RPT-193Latest Information Update: 28 Jun 2024
At a glance
- Originator RAPT Therapeutics
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Skin disorder therapies; Small molecules
- Mechanism of Action CCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Asthma; Atopic dermatitis
- No development reported Hypersensitivity